CLINICAL_TRIALS
trial_result
· 2014-05-12
Clinical Trial Update: Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma [Phase 2]
Summary
A Phase II study of SOM230 (pasireotide) in patients with recurrent or progressive meningioma was terminated, and results were posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Utah | Conditions: Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-05-12